MedPath
HSA Product

SINGULAIR TABLET 10 mg

Product approved by Health Sciences Authority (SG)

Basic Information

SINGULAIR TABLET 10 mg

TABLET

Regulatory Information

SIN09769P

May 16, 1998

Prescription Only

Therapeutic

ORAL

August 10, 2023

May 30, 2025

XR03DC03

Company Information

ORGANON SINGAPORE PTE. LTD.

ORGANON SINGAPORE PTE. LTD.

Active Ingredients

Detailed Information

Contraindications

**V. CONTRAINDICATIONS** - Hypersensitivity to any component of this product

Indication Information

**II. INDICATIONS** SINGULAIR is indicated in adult and pediatric patients 1 year of age and older for the prophylaxis and chronic treatment of asthma, including the prevention of day- and nighttime symptoms, the treatment of aspirin-sensitive asthmatic patients, and the prevention of exercise-induced bronchoconstriction. SINGULAIR is indicated for the relief of daytime and nighttime symptoms of allergic rhinitis (seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older, and perennial allergic rhinitis in adults and pediatric patients 1 year of age and older). Because the benefits of SINGULAIR may not outweigh the risk of neuropsychiatric symptoms in patients with allergic rhinitis, reserve use for patients who have an inadequate response or intolerance to alternative therapies.

© Copyright 2025. All Rights Reserved by MedPath